SURAKSHA DIAGNOSTIC
|
|
BOM : 544293     NSE : SURAKSHA     | |
LT :  
    Long Term Analysis
Fundamentals : Good
Valuation : Bad [Stock is Expensive] Debt : Low |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Feb 21,2025 |
Price(EOD): ₹ 300.35
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Hospital & Healthcare Services |
MCap: ₹ 1,564.82 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
SURAKSHA DIAGNOSTIC | 4.9% | -6.5% | NA |
MAX HEALTHCARE INSTITUTE | -0.5% | -4.2% | 21.2% |
APOLLO HOSPITALS ENTERPRISE | 0.3% | -6.3% | -5.4% |
FORTIS HEALTHCARE | 1% | 0.4% | 36.8% |
GLOBAL HEALTH | 9.2% | 17.9% | -15.4% |
NARAYANA HRUDAYALAYA | 5.5% | 7.2% | 3.8% |
KRISHNA INSTITUTE OF MEDICAL SCIENCES | -4.2% | -11.6% | 22.2% |
DR LAL PATHLABS | -1.1% | -8.1% | 8.2% |
ASTER DM HEALTHCARE | 2% | -16.1% | -11.9% |
FUNDAMENTAL ANALYSIS OF SURAKSHA DIAGNOSTIC
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF SURAKSHA DIAGNOSTIC
 Ratio | Consolidated | |
---|---|---|
P/E P/B P/S |
53.91
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 29.02 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] 8.72
P/B Calculated based on Book Value of Rs 179.41 Cr
[Latest Year - Mar2024 - Consolidated Results ] 6.57
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 238.14 Cr
[Latest Qtr - Dec2024 - Consolidated Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
1829% 2056% - |
SHARE PRICE MOMENTUM OF SURAKSHA DIAGNOSTIC
SURAKSHA DIAGNOSTIC vs SENSEX
DEBT OF SURAKSHA DIAGNOSTIC
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2024 2023 2022 Avg_3yrs |
0.05 0.09 0.13 0.09 |
0.05 0.09 0.13 0.09 |
[Last Annual Data : Mar2024]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF SURAKSHA DIAGNOSTIC
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2024 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF SURAKSHA DIAGNOSTIC
Consolidated | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
-10.85% -21.29% -40.99% -41.09% |
NA 58.9% NA NA |
QtrlyTrend |
-3 | |
Latest Qtr: Dec2024 | ||
Quarterly Result Analysis → |
SURAKSHA DIAGNOSTIC related INDICES
BSE Indices | 1W | 1M | 1Y |
---|---|---|---|
BSE IPO | 0.3% | -7.9% | -2.3% |
NSE Indices | 1W | 1M | 1Y |
---|---|---|---|
NIFTY IPO INDEX | 0.5% | -8.6% | NA |
You may also like the below Video Courses
FAQ about SURAKSHA DIAGNOSTIC
Is SURAKSHA DIAGNOSTIC good for long term investment?
As on Feb 21,2025, the Fundamentals of SURAKSHA DIAGNOSTIC look Strong and hence it may be good for long term investment! See Financial Performance of SURAKSHA DIAGNOSTIC . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is SURAKSHA DIAGNOSTIC UnderValued or OverValued?
As on Feb 21,2025, SURAKSHA DIAGNOSTIC is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of SURAKSHA DIAGNOSTIC ?
As on Feb 21,2025, the Intrinsic Value of SURAKSHA DIAGNOSTIC is Rs. 14.75 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. 15.57
Fair Value [Median EV / Sales Model] : Rs. 13.93
Fair Value [Median Price / Sales Model] : Rs. 0.00
Estimated Median Fair Value of SURAKSHA DIAGNOSTIC : Rs. 14.75
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.